Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma

Prognostic significance of bcl-2, c-myc, survivin and tumor grade in synovial sarcoma

“…A correlation has recently been found between the bcl-2 m-RNA level and immunohistochemical expression severity and diffuseness in 32 synovial sarcoma cases where the SS18/SSX1 or SS18/SSX2 fusion gene was detected on PCR. A higher metastasis rate and shorter life was found in eases with more bel-2 immunohistoehemieal expression in the same study but this finding was not statistieally significant (13). The disease-free survival duration was signifieantly shorter in cases showing strong positively bcl-2 staining than in bcl-2 negative and focal faint positive cases in our study.…”

“…For example, a eorrelation has been found between bel-2 expression and unfavorable histologieal parameters and elinieal eourse in tumors sueh as neuroblastoma and Ewing sarcoma (24). Bcl-2 positivity in synovial sarcoma (highly diffuse positive) is a well-known finding (6,25 -27) but its relationship with prognosis is unclear (13). A correlation has recently been found between the bcl-2 m-RNA level and immunohistochemical expression severity and diffuseness in 32 synovial sarcoma cases where the SS18/SSX1 or SS18/SSX2 fusion gene was detected on PCR.…”

“…The immune expressions of bcl-2, c-myc and survivin in different types of sarcoma and synovial sarcoma cases and their relationship with the prognosis have previously been investigated (13)(14)(15)(16)(17). Our aim in this study was to immunohistochemically evaluate the relationship between bcl-2, c-myc, survivin expression and the prognosis of synovial sarcoma because literature findings on the relationship of bcl-2 and c-myc immune expression with the prognosis are not clear.…”

Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for Therapy

“…The tumor's propensity in many cases for slow growth, late recurrences and chemotherapy resistance is consistent with an antiapoptotic phenotype. A striking feature of synovial sarcoma is its consistently very high expression of BCL2 (59, 76, 77), but no evidence has been found that the BCL2 gene is a direct target for transcriptional upregulation by SS18-SSX; therefore, its high level of expression may be a secondary oncogenic effect, or may reflect a prerequisite cellular background to be permissive for SS18-SSX. In contrast, the BCL2 family members BCL2A1 and MCL1 are direct targets for SS18-SSX-mediated repression.…”

Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities

“…Immunohistochemical and molecular studies have demonstrated high expression levels of the anti-apoptotic protein BCL-2 (B-cell CLL/lymphoma 2) in the majority of SS tumors 63 . Due to the absence of genomic amplifications or rearrangements, overexpression of BCL-2 may result from transcriptional activation 64 .…”